Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Joan H. Schiller, David Harrington, Chandra P. Belani et al. · New England Journal of Medicine · 2002 · 4.9K citations

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

J Oan H. S Chiller, D Avid H Arrington, C Handra P. B Elani et al. · 2002 · 3.7K citations

Median Survival, Medicine, Cancer Management +13

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

A. Hilary Calvert, David R. Newell, Lindsey Gumbrell et al. · Journal of Clinical Oncology · 1989 · 1.9K citations

Pharmacotherapy, Physiologically-based Pharmacokinetic Modeling, Pharmacokinetics +16

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Martin Reck, Joachim von Pawel, Petr Zatloukal et al. · Journal of Clinical Oncology · 2009 · 1.5K citations